{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:26:24Z","timestamp":1793651184362,"version":"4.5.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL139671"],"award-info":[{"award-number":["R01HL139671"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG081582-01"],"award-info":[{"award-number":["R01AG081582-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL139671"],"award-info":[{"award-number":["R01HL139671"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG081582\u201001"],"award-info":[{"award-number":["R01AG081582\u201001"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Transthyretin cardiomyopathy (ATTR-CM) is characterized by episodes of worsening heart failure (WHF) which can include heart failure (HF) hospitalizations or urgent unplanned visits for administration of intravenous diuretics. WHF characterized by outpatient intensification of oral loop diuretics is common yet its prognostic implications for ATTR-CM patients relative to other WHF events remains unclear. We assessed how WHF characterized by outpatient diuretic intensification (ODI) relates to mortality in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This was a retrospective study of ATTR-CM patients presenting to the Columbia University Irving Medical Center. Oral loop diuretic dose was recorded longitudinally. WHF characterized by ODI was defined as a persistent increase in oral loop diuretic dose lasting &amp;gt;1\u2009month. We analysed the all-cause mortality rate after either WHF event (hospitalization or ODI) relative to subjects who had no WHF event. Overall, 303 patients highly treated with tafamidis were included: 152 (50.2%) patients had no WHF events, 35 (11.6%) experienced HF hospitalization, and 145 (47.9%) experienced ODI; 29 (9.6%) patients experienced both WHF events. Patients experiencing ODI had higher rates of subsequent mortality (17.7 per 100 person-years; 95% confidence interval [CI] 13.3\u201323.7) as did those with a HF hospitalization (29.8 per 100 person-years; 95% CI 17.7\u201350.3) than patients without WHF events (5.0 per 100 person-years; 95% CI 3.0\u20138.3) on log-rank test. WHF characterized by ODI was independently associated with mortality in a model adjusting for age, genotype, atrial fibrillation, disease duration, time-varying tafamidis use and National Amyloid Centre (NAC) or Columbia stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In contemporary patients with ATTR-CM treated with tafamidis, WHF requiring ODI is prognostic of subsequent mortality and is a clinical marker of disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3540","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T23:10:17Z","timestamp":1733440217000},"page":"2961-2970","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Outpatient Worsening of Heart Failure and Mortality in Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3953-219X","authenticated-orcid":false,"given":"Lawrence","family":"Zeldin","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna B.S.","family":"Eichler","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-9330","authenticated-orcid":false,"given":"Sergio L.","family":"Teruya","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4778-9582","authenticated-orcid":false,"given":"Ariel Y.","family":"Weinsaft","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonsina","family":"Mirabal","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret O.","family":"Cuomo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Mateo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Helmke","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-5008","authenticated-orcid":false,"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"2026021721512207600_ejhf3540-bib-0001","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026021721512207600_ejhf3540-bib-0002","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","article-title":"Characteristics and natural history of early-stage cardiac transthyretin amyloidosis","volume":"43","author":"Law","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021721512207600_ejhf3540-bib-0003","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/ejhf.2874","article-title":"Worsening of chronic heart failure: Definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Metra","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021721512207600_ejhf3540-bib-0004","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","article-title":"Worsening heart failure: Nomenclature, epidemiology, and future directions: JACC review topic of the week","volume":"81","author":"Greene","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721512207600_ejhf3540-bib-0005","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1007\/s00392-021-01851-w","article-title":"Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction","volume":"110","author":"Coiro","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2026021721512207600_ejhf3540-bib-0006","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ejhf.462","article-title":"Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction","volume":"18","author":"Damman","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026021721512207600_ejhf3540-bib-0007","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","article-title":"Importance of clinical worsening of heart failure treated in the outpatient setting","volume":"133","author":"Okumura","year":"2016","journal-title":"Circulation"},{"key":"2026021721512207600_ejhf3540-bib-0008","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/ejhf.2376","article-title":"Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: An analysis from TOPCAT","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721512207600_ejhf3540-bib-0009","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.123.066506","article-title":"Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial","volume":"148","author":"Chatur","year":"2023","journal-title":"Circulation"},{"key":"2026021721512207600_ejhf3540-bib-0010","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021721512207600_ejhf3540-bib-0011","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","article-title":"Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid","volume":"18","author":"Hutt","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026021721512207600_ejhf3540-bib-0012","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-Evidence base and standardized methods of imaging","volume":"25","author":"Dorbala","year":"2019","journal-title":"J Card Fail"},{"key":"2026021721512207600_ejhf3540-bib-0013","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016010","article-title":"One-year mortality after intensification of outpatient diuretic therapy","volume":"9","author":"Madelaire","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026021721512207600_ejhf3540-bib-0014","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021721512207600_ejhf3540-bib-0015","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021721512207600_ejhf3540-bib-0016","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/ejhf.1796","article-title":"Association between loop diuretic dose changes and outcomes in chronic heart failure: Observations from the ESC-EORP Heart Failure Long-Term Registry","volume":"22","author":"Kapelios","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021721512207600_ejhf3540-bib-0017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021721512207600_ejhf3540-bib-0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021721512207600_ejhf3540-bib-0019","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021721512207600_ejhf3540-bib-0020","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026021721512207600_ejhf3540-bib-0021","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.mayocp.2021.04.021","article-title":"Early diagnosis and outcome in patients with wild-type transthyretin cardiac amyloidosis","volume":"96","author":"Fumagalli","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2026021721512207600_ejhf3540-bib-0022","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.cardfail.2024.02.014","article-title":"Temporal outcomes of patients diagnosed with transthyretin cardiac amyloidosis","volume":"30","author":"Chan","year":"2024","journal-title":"J Card Fail"},{"key":"2026021721512207600_ejhf3540-bib-0023","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20\u2009years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"2026021721512207600_ejhf3540-bib-0024","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1007\/s12325-024-02891-0","article-title":"Advancing transthyretin amyloidosis drug development in an evolving treatment landscape: Amyloidosis Forum Meeting Proceedings","volume":"41","author":"Maurer","year":"2024","journal-title":"Adv Ther"},{"key":"2026021721512207600_ejhf3540-bib-0025","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): A randomised controlled trial","volume":"398","author":"Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"2026021721512207600_ejhf3540-bib-0026","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1002\/ehf2.13043","article-title":"Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak","volume":"7","author":"Severino","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026021721512207600_ejhf3540-bib-0027","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026021721512207600_ejhf3540-bib-0028","author":"U.S. Food and Drug Administration. Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. Guidance for Industry. March 2019"},{"key":"2026021721512207600_ejhf3540-bib-0029","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026021721512207600_ejhf3540-bib-0030","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaccao.2024.05.001","article-title":"Race and socioeconomic status impact diagnosis and clinical outcomes in transthyretin cardiac amyloidosis","volume":"6","author":"Shankar","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026021721512207600_ejhf3540-bib-0031","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ejhf.3088","article-title":"Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?","volume":"26","author":"Razvi","year":"2024","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/12\/2961\/66836727\/eurjhf_27_12_2961.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/12\/2961\/66836727\/eurjhf_27_12_2961.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:51:29Z","timestamp":1771383089000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/12\/2961\/8470613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3540","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"2024-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}